Tirzepatide vs Retatrutide
Comparing the next-generation GLP-1 compounds: the FDA-approved dual agonist against the investigational triple agonist with the largest weight loss results ever recorded in clinical trials.
Tirzepatide is an FDA-approved prescription medication. Retatrutide is an investigational compound not approved for any use. This comparison is for educational purposes only.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist that simultaneously activates both incretin hormone receptors. FDA-approved for type 2 diabetes (2022) and chronic weight management (2023), it represents the second generation of GLP-1 therapeutics. The SURMOUNT-1 trial demonstrated average weight loss of up to 22.5% of body weight at the 15mg weekly dose over 72 weeks. Tirzepatide’s dual mechanism provides both appetite suppression through GLP-1 and enhanced insulin sensitivity and lipid metabolism through GIP receptor activation.
What Is Retatrutide?
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It builds on tirzepatide’s dual agonist approach by adding glucagon receptor activation, which increases basal metabolic rate and drives hepatic fat oxidation. This means retatrutide not only suppresses appetite (GLP-1 + GIP) but also increases energy expenditure (glucagon) — a combination that produced the largest weight loss ever seen in an obesity clinical trial. Phase 2 data showed 24.2% average weight loss at 12mg over 48 weeks, and Phase 2 data also showed rapid resolution of metabolic-associated steatotic liver disease (MASLD) in most participants.
Dual vs Triple Agonism
Both tirzepatide and retatrutide share GLP-1 and GIP receptor activation — this gives them comparable appetite-suppressing effects. The differentiator is retatrutide’s glucagon receptor agonism. Glucagon signals the liver to convert stored glycogen and fat into usable energy, effectively increasing total energy expenditure. In clinical terms, tirzepatide primarily works by reducing caloric intake, while retatrutide both reduces intake AND increases expenditure. This dual-direction effect may explain the modestly greater weight loss seen in retatrutide trials. However, glucagon agonism also requires careful glucose monitoring and introduces theoretical hepatic risks that are still being evaluated in Phase III studies.
Side-by-Side Comparison
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual GIP/GLP-1 agonist | Triple GLP-1/GIP/glucagon agonist |
| Max Weight Loss (trials) | Up to 22.5% | Up to 24.2% |
| Administration | Subcutaneous (weekly) | Subcutaneous (weekly) |
| FDA Status | Approved (2022/2023) | Phase III trials |
| Energy Expenditure | Indirect only | Increased (via glucagon) |
| Liver Fat Reduction | Moderate | Rapid (Phase 2 data) |
Related Reading
- Semaglutide vs Tirzepatide — the most common GLP-1 comparison
- Semaglutide vs Retatrutide — established vs experimental GLP-1 agents
- GLP-1 for Weight Loss — clinical weight loss data for GLP-1 peptides
- What Is GLP-1? — introduction to GLP-1 receptor agonists
Frequently Asked Questions
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. Retatrutide adds glucagon receptor activation, which increases energy expenditure and hepatic fat oxidation.
Which produces more weight loss — tirzepatide or retatrutide?
Phase 2 data shows retatrutide producing up to 24.2% average weight loss, compared to tirzepatide’s 22.5%. However, Phase III data is needed for definitive comparison.
Is retatrutide available?
No. Retatrutide is in Phase III clinical trials and is not approved or available. Tirzepatide is FDA-approved and available by prescription.
Further Reading & Research
Explore independent research databases and regulatory resources.
Medical Disclaimer: Tirzepatide is a prescription medication. Retatrutide is an investigational compound not approved for any use. This content is for educational and research purposes only and does not constitute medical advice.